Furthermore, there is strong in vitro and in vivo biological evidence that TBX2 and TBX3 are novel targets for the development of anti‐cancer drugs that can be administered on their own or in combination with current chemotherapeutic DNA‐damaging drugs such as cisplatin [11, 12, 13, 14, 15, 16]. The gene discussed is TBX2; the disease is cancer.